Attitude towards antiretroviral Pre-Exposure Prophylaxis (PrEP) prescription among HIV specialists.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMC 3658955)

Published in BMC Infect Dis on May 14, 2013


Vincenzo Puro1, Antonio Palummieri, Gabriella De Carli, Pierluca Piselli, Giuseppe Ippolito

Author Affiliations

1: UOC Infezioni emergenti e Centro di riferimento AIDS - Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, via Portuense, 292, 00161, Rome, Italy.

Associated clinical trials:

PC4PrEP: Integrating PrEP Into Primary Care (PC4PrEP) | NCT03617874

Articles citing this

HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav (2014) 2.00

How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav (2014) 1.93

Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. AIDS Behav (2015) 1.49

Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. PLoS One (2015) 1.15

The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav (2014) 1.07

A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. J Gen Intern Med (2016) 1.00

Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS One (2014) 0.97

PrEP Awareness and Attitudes in a National Survey of Primary Care Clinicians in the United States, 2009-2015. PLoS One (2016) 0.92

Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs (2015) 0.90

How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores". Am J Public Health (2015) 0.87

Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP. J Acquir Immune Defic Syndr (2015) 0.87

Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep (2014) 0.86

Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav (2016) 0.78

Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. AIDS Behav (2016) 0.77

The European preexposure prophylaxis revolution. Curr Opin HIV AIDS (2016) 0.76

Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers. Medicine (Baltimore) (2016) 0.75

Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS One (2017) 0.75

Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic. Curr HIV/AIDS Rep (2017) 0.75

Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Front Immunol (2017) 0.75

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03

The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol (2000) 7.77

Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep (2012) 2.95

Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS One (2012) 2.82

A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One (2012) 2.21

Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J (2012) 2.19

Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr (2012) 2.19

Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS (2012) 1.86

The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. Int J STD AIDS (2012) 1.59

Using focus groups to develop health surveys: an example from research on social relationships and AIDS-preventive behavior. Health Educ Q (1993) 1.50

Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS (2012) 1.40

Informing faith-based HIV/AIDS interventions: HIV-related knowledge and stigmatizing attitudes at Project F.A.I.T.H. churches in South Carolina. Public Health Rep (2010) 1.17

Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care (2013) 1.04

HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis (2012) 0.90

HIV care providers and prevention: opportunities and challenges. J Acquir Immune Defic Syndr (2004) 0.88

HIV incidence among men who have sex with men prescribed postexposure prophylaxis. AIDS (2012) 0.81

Clinical decisions. Preexposure prophylaxis for HIV prevention--polling results. N Engl J Med (2012) 0.80

The epidemic of HIV infection and AIDS, promotion of testing, and innovative strategies. Ann Ist Super Sanita (2010) 0.79

Articles by these authors

Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr (2004) 2.22

Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol (2008) 2.13

Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis (2008) 1.98

Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol (2005) 1.87

Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar. Int J Infect Dis (2011) 1.78

High HIV prevalence in male patients with acute hepatitis A in the Rome metropolitan area, Italy 2002-2008. J Hepatol (2011) 1.71

Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56

Anthrax toxin: a tripartite lethal combination. FEBS Lett (2002) 1.54

Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses (2005) 1.52

Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52

Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol (2004) 1.50

Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. Am J Trop Med Hyg (2009) 1.47

Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res (2007) 1.45

Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40

Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med (2015) 1.39

Scalp needlestick injury during fine-needle aspiration cytologic evaluation without needle manipulation: William tell in the laboratory, not quite. Infect Control Hosp Epidemiol (2006) 1.39

Cancer incidence in people with AIDS in Italy. Int J Cancer (2010) 1.39

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35

Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer (2008) 1.33

Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis (2009) 1.32

Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest (2015) 1.30

Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses (2003) 1.29

Networking for infectious-disease emergencies in Europe. Nat Rev Microbiol (2008) 1.28

Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Euro Surveill (2016) 1.28

Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med (2007) 1.23

Alkhurma hemorrhagic fever in travelers returning from Egypt, 2010. Emerg Infect Dis (2010) 1.22

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med (2011) 1.21

Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.21

Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis (2010) 1.20

Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med (2009) 1.19

Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis (2010) 1.18

Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One (2010) 1.18

Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr (2003) 1.15

Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med (2016) 1.15

Molecular epidemiology of a Pseudomonas aeruginosa hospital outbreak driven by a contaminated disinfectant-soap dispenser. PLoS One (2011) 1.14

IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis (2011) 1.12

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol (2004) 1.08

Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease. Lancet Infect Dis (2009) 1.06

Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med (2003) 1.06

Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol (2003) 1.06

Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05

Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest (2015) 1.04

IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect (2010) 1.04

Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. BMC Infect Dis (2012) 1.04

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis (2005) 1.04

Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. Am J Trop Med Hyg (2007) 1.04

Case definition for Ebola and Marburg haemorrhagic fevers: a complex challenge for epidemiologists and clinicians. New Microbiol (2009) 1.03

Crimean-Congo hemorrhagic fever, southwestern Bulgaria. Emerg Infect Dis (2009) 1.03

Simple and reliable method for detection and genotyping of hepatitis C virus RNA in dried blood spots stored at room temperature. J Clin Microbiol (2002) 1.01

Behavioral correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.01

Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology (2011) 1.01

Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr (2007) 1.01

Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis (2011) 1.01

The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLoS One (2013) 1.00

Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. Clin Transl Gastroenterol (2012) 1.00

Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS (2011) 0.98

Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors. World J Surg (2006) 0.98

Surgical site infections in Italian Hospitals: a prospective multicenter study. BMC Infect Dis (2008) 0.98

Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis (2009) 0.98

Frequency of detection of upper respiratory tract viruses in patients tested for pandemic H1N1/09 viral infection. J Clin Microbiol (2010) 0.98

How many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance data. AIDS (2016) 0.97

Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis (2002) 0.97

Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02). J Clin Microbiol (2004) 0.96

Presence of the A226V mutation in autochthonous and imported Italian chikungunya virus strains. Clin Infect Dis (2008) 0.96

Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). J Acquir Immune Defic Syndr (2002) 0.96

A molecular beacon, bead-based assay for the detection of nucleic acids by flow cytometry. Nucleic Acids Res (2005) 0.95

Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis (2006) 0.95

Impact of hepatitis C virus infection on lifestyle. World J Gastroenterol (2007) 0.95

Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. Eur J Cancer (2008) 0.94

Cat-to-human orthopoxvirus transmission, northeastern Italy. Emerg Infect Dis (2009) 0.93

Healthcare-associated infection in Italy: annual point-prevalence surveys, 2002-2004. Infect Control Hosp Epidemiol (2009) 0.93

Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis. Clin Dev Immunol (2012) 0.93

Design and clinical application of a molecular method for detection and typing of the influenza A/H1N1pdm virus. J Virol Methods (2009) 0.92

Occupational transmission of hepatitis C virus. JAMA (2002) 0.92

Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya. AIDS Res Hum Retroviruses (2002) 0.92

Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. AIDS (2002) 0.92

Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008-2009. J Clin Virol (2012) 0.92

Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS (2002) 0.91

IgG against dengue virus in healthy blood donors, Zanzibar, Tanzania. Emerg Infect Dis (2014) 0.91

HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis (2012) 0.90

Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res (2013) 0.90

Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J Proteome Res (2012) 0.90

Criteria for discharge of patients with Ebola virus diseases in high-income countries. Lancet Glob Health (2015) 0.90

Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy. J Clin Virol (2012) 0.89

Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther (2005) 0.89

Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin Infect Dis (2002) 0.89

European perspective of 2-person rule for biosafety level 4 laboratories. Emerg Infect Dis (2009) 0.88

The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infect Dis (2013) 0.88

High-level tolerance to triclosan may play a role in Pseudomonas aeruginosa antibiotic resistance in immunocompromised hosts: evidence from outbreak investigation. BMC Res Notes (2012) 0.88

Border screening for SARS. Med J Aust (2004) 0.88

Zika Virus Infection in the Central Nervous System and Female Genital Tract. Emerg Infect Dis (2016) 0.86

Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic. PLoS Curr (2010) 0.86